Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors

Tsuchida, Yoshiaki; Honna, Toshiro; Iwanaka, Tadashi; Saeki, Morihisa; Taguchi, Nobuyuki; Kaneko, Takashi; Koide, R; Yukiko, Tsunematsu; Shimizu, Kohichi; Makino, Shin-ichi; Hashizume, Kohei; Nakajo, Toshio

doi:10.1016/s0022-3468(87)80261-0

Cited by 27 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, a significantly lower NSE value was observed in the most rapidly grow ing TNB1, with amplification of all three DNA sequences and a DNA rearrangement. An up-to-12-fold range of NSE expression was reported in human neuroblastoma cell lines [29] and in neuroblastoma patients [30]. It could be speculated, therefore, that gene amplification may be responsible for a lower expression of the tumor markers.…”

Section: Discussionmentioning

confidence: 98%

Clinical Significance of Gene Amplification Studied in Human Neuroblastoma Xenografts: Relationship with Tumor Growth Rate, Chemotherapeutic Sensitivities and Levels of Neuron-Specific Enolase

Tsuchida

Kanda²,

Shimatake³

et al. 1988

Pathobiology

Self Cite

View full text Add to dashboard Cite

Tumor doubling time, sensitivity to chemotherapeutic agents and concentrations of neuron-specific enolase were studied in nine human neuroblastoma xenografts, in which amplifications of N-myc, clones 8 and G21 were known; N-myc was amplified in eight, clone 8 in five and clone G21 in four of these nine xenografts. Tumor doubling time was longest in one xenograft, TNB10, which lacks the amplification of either N-myc or clone 8 or G21 and shortest in TNB1 in which all three DNA sequences are amplified with a DNA rearrangement in clone 8. No correlations were found between genomic amplification of N-myc, clones 8 and G21 and effectiveness of five chemotherapeutic drugs tested, except for cis-platinum. cis-Platinum was found to be effective on all but the one xenograft, TNB 10, with the longest tumor doubling time. Concentration of neuron-specific enolase in tumor extract was lowest in TNB1 and correlated with the length of the tumor doubling time.

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical Significance of Gene Amplification Studied in Human Neuroblastoma Xenografts: Relationship with Tumor Growth Rate, Chemotherapeutic Sensitivities and Levels of Neuron-Specific Enolase

Tsuchida

Kanda²,

Shimatake³

et al. 1988

Pathobiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…From the literature NSE seems to be a good biomarker in neuroblastoma patients. Notomi et al [28], Tsuchida et al [29] and Ishiguro et al [30] demonstrated that serum NSE was abnormally high in children with neuroblastoma. Ishiguro et al [13] tested NSE serum levels in 18 neuroblastoma patients and in 40 healthy infants (control group).…”

Section: Discussionmentioning

confidence: 99%

Neuron-Specific Enolase Evaluation in Patients with Neuroblastoma

Massaron¹,

Seregni

Luksch

et al. 1998

Tumor Biol

View full text Add to dashboard Cite

Neuron-specific enolase (NSE) may be of interest for the prognostic evaluation and follow-up surveillance in patients with neuroblastoma. We evaluated NSE levels in 80 patients with neuroblastoma. The marker correlated with stage (in stage 1 patients, the median NSE level was 9.9 ng/ml, in stage 2, 45.1 ng/ml, in stage 3, 49 ng/ml, in stage 4, 93.9 ng/ml, in stage 4S, 53.4 ng/ml) and with survival. In patients with a favorable or a poor outcome, the difference in basal NSE serum levels was statistically significant (p = 0.0001). Serial measurements revealed that there was a good correlation between NSE levels and disease course. We concluded that NSE is a good marker for neuroblastoma and its quantitative determination in serum is valuable in the management of these patients to confirm the diagnosis, monitor the effect of treatment and detect recurrent disease.

show abstract

“…Neuron-specific enolase (NSE) is a cell-specific isoenzyme of the glycolytic enzyme enolase and is a highly specific marker for neurons and peripheral neuroendocrine cells. [65][66][67][68] There are three isozymes of enolase which are expressed by different genes in mammals, namely alpha enolase which is ubiquitous, beta enolase which is muscle-specific and gamma enolase which is neuronspecific, and the three isoforms are characterised by different tissue distributions and by distinct biochemical and immunological properties. 65,67,68 The human NSE is a major brain protein that constitutes between 0•4 and 2•2% of the total soluble protein of brain, depending on the region and in some neurons accounts for 3-4% of the total soluble protein.…”

Section: Neuron-specific Enolase (Nse)mentioning

confidence: 99%

Liquid biomarkers for the management of paediatric neuroblastoma: an approach to personalised and targeted cancer therapy

et al. 2020

View full text Add to dashboard Cite

Background: Neuroblastoma is the most common extracranial solid tumour of infancy and accounts for about 6–10% of paediatric cancers. It has a biologically and clinically heterogeneous behaviour that ranges from spontaneous regression to cases of highly aggressive metastatic disease that could be unresponsive to standard therapy. In recent years, there have been several investigations into the development of various diagnostic, predictive and prognostic biomarkers towards personalised and targeted management of the disease. Materials and Methods: This paper reports on the review of current clinical and emerging biomarkers used in risk assessment, screening for early detection and diagnosis, prognostication and monitoring of the response of treatment of neuroblastoma in paediatric patients. Conclusions: Tumour markers can significantly improve diagnosis; however, the invasive, unpleasant and inconvenient nature of current tissue biopsies limits their applications, especially in paediatric patients. Therefore, the development of a non-invasive, reliable high accurate and personalised diagnostic tool capable of early detection and rapid response is the most promising step towards advanced cancer management from tumour diagnosis, therapy to patient monitoring and represents an important step towards the promise of precision, personalised and targeted medicine. Liquid biopsy assay with wide ranges of clinical applications is emerging to hold incredible potential for advancing cancer treatment and has greater promise for diagnostic purposes, identification and tracking of tumour-specific alterations during the course of the disease and to guide therapeutic decisions.

show abstract

Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors

Cited by 27 publications

References 16 publications

Clinical Significance of Gene Amplification Studied in Human Neuroblastoma Xenografts: Relationship with Tumor Growth Rate, Chemotherapeutic Sensitivities and Levels of Neuron-Specific Enolase

Clinical Significance of Gene Amplification Studied in Human Neuroblastoma Xenografts: Relationship with Tumor Growth Rate, Chemotherapeutic Sensitivities and Levels of Neuron-Specific Enolase

Neuron-Specific Enolase Evaluation in Patients with Neuroblastoma

Liquid biomarkers for the management of paediatric neuroblastoma: an approach to personalised and targeted cancer therapy

Contact Info

Product

Resources

About